Navigation Links
Oncothyreon reports first quarter 2009 financial results
Date:5/14/2009

storical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding future expenses, clinical development activities and the use and adequacy of cash resources.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing our product candidates, the adequacy of financing and cash reserves on hand, changes in general accounting policies, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on SEDAR at www.sedar.com.

'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon regains compliance with NASDAQ listing requirements
2. Oncothyreon to present at Invest Northwest 2009
3. Oncothyreon reports full year and fourth quarter 2008 financial results
4. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
5. Oncothyreon to present at BIO CEO & Investor Conference 2009
6. Oncothyreon reports third quarter 2008 financial results
7. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
8. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
9. Oncothyreon to present at BIO Investor Forum 2008
10. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
11. Oncothyreon announces prioritization plan for development programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 2015 , ... In her thought provoking debut novel ‘ Ebola Vaccine Wars ... faced with an Ebola pandemic that is on the cusp of wiping out humanity. ... world of counterterrorism, and who continues to appear in this series of books by ...
(Date:9/1/2015)... ... 01, 2015 , ... Leading CEOs, CSOs, CMOs, and heads ... join prominent academics and key investors for Neuro Advance Boston, October 14, 2015 ... , Neuro Advance Boston focuses on the latest developments and opportunities in ...
(Date:9/1/2015)... ... , ... A new host-based therapy for Ebola, anthrax and ... Institute and its collaborators. The discovery has the potential to speed to market ... 27 by Scientific Reports, an open access research journal from the publishers of ...
(Date:8/31/2015)... ... 31, 2015 , ... The Global Supply Chain Resiliency Council ... resiliency practitioners with luminaries and thought leaders to advance the professional discipline through ... innovations and performance excellence. At that time its principle sponsor, Resilinc , ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... ground-breaking treatment option for victims of whiplash associated disorders (WAD). ... Z Therapy is the first and only rehabilitation specialist in North ... neck pain. , ... Dallas, TX (PRWEB) April 21, ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the first quarter ... before the opening of the financial markets.NxStage will also ... on Friday, May 8, 2009 to discuss its first ...
... LLC announced today that it has issued an Executive ... 56-page report can be found at www.crystalra.com ... is a closely held pharmaceutical company focused exclusively on ... a technology spinout from Bayer HealthCare LLC, ACT Biotech ...
Cached Biology Technology:Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers 2NxStage to Report First Quarter 2009 Financial Results 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... faced with everyday obstacles in their physical environments and ... with them. Navigating these obstacles can involve highly complex ... work, researchers have employed an ingenious obstacle-based system for ... in the fruit fly Drosophila. , The findings ...
... tailored therapiesContinuing its strong support for studies on ... Institutes of Health anticipates spending more than $150 ... Research Network (PGRN). The research of this nationwide ... drug prescriptions to people's unique genetic make-ups. ...
... have found a family of proteins that enhances the sensitivity ... growth and cancer. Their discovery could lead to a completely ... new drugs to stop uncontrolled growth in a wide variety ... Oxford, funded in part by the Biotechnology and Biological Sciences ...
Cached Biology News:Gap-climbing fruit flies reveal components of goal-driven behaviors 2NIH renews network focused on how genes influence drug responses 2NIH renews network focused on how genes influence drug responses 3NIH renews network focused on how genes influence drug responses 4Fruit fly studies open new window on cancer research 2
... Peptide sequences: Two separate vials ... to the same sequence used as ... (Catalog No. 160890) ... Cayman's guanylate cyclase polyclonal antiserum (Catalog ...
... 3B8A10. Immunogen: Recombinant ... C-terminal region of human ... for the human ubiquilin ... (positive control: 293 cells). ...
... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
... The versatile Zymo-Spin I-96 Plate can be ... manifolds for the large-scale (i.e., 96-well) purification ... polypropylene construction and unique silica-based matrix make ... g DNA or RNA in = 10 ...
Biology Products: